New Strategies Needed As China Shakes Up Drug Class Rules?
This article was originally published in SRA
Like a stone being thrown into a pool of calm water, the China Food and Drug Administration released on March 9 "Document 51, Reform Plans for Chemical Drug Registration", stirring up immediate reactions from the pharma industry1.
You may also be interested in...
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.